Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Inclusion Criteria: * Patients with PD duration between 1 month and 3 months. * Patients aged between 18 and 75 years. * Voluntary signing of informed consent. * Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present. * Daily urine output ≥ 400ml/day. * Stable PD prescription for one month. Exclusion Criteria: * Pregnant and lactating women. * Patients with type 1 diabetes mellitus. * Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past. * Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe liver diseases. * Patients with more than 2 episodes of urinary tract infection in the past six months. * Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin. * Patients using the following medications: rifampicin, phenytoin. * Patients with malignant tumors. * Patients who developed peritonitis within one month. * Patients undergoing combined hemodialysis treatment. * Patients with a willingness for kidney transplantation within six months. * Patients with a history of pancreatitis or pancreatic transplantation. * Patients who experienced acute coronary syndrome or cerebrovascular events within one month. * Hemoglobin level less than 90g/L.